MYC通过CD47和PD-L1调节抗瘤免疫反应
Stephanie C Casey1, Ling Tong1, Yulin Li1
1Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Science (New York, N.Y.)
|March 12, 2016
概括
通过控制免疫检查点CD47和PD-L1来驱动癌症. 抑制MYC可以降低这些检查点,增强抗瘤免疫力,阻碍癌症生长.
科学领域:
- 癌症学
- 免疫学
- 分子生物学
背景情况:
- 在人类癌症中,MYC瘤基因经常过度表达.
- MYC是一种转录因子,参与细胞生长和增殖.
- 免疫检查点,如CD47和PD-L1,在瘤免疫逃避中发挥关键作用.
研究的目的:
- 研究MYC在调节免疫检查点蛋白CD47和PD-L1中的作用.
- 要确定MYC是否直接影响CD47和PD-L1的表达.
- 阐明MYC介导免疫检查点对抗瘤免疫反应的影响.
主要方法:
- 在小鼠瘤模型和人类瘤细胞系中诱导MYC抑制.
- 对CD47和PD-L1mRNA和蛋白质水平进行定量分析.
- 染色体免疫沉测试以评估MYC与基因促进体的结合.
- 在MYC失活后对抗瘤免疫反应的评估.
主要成果:
- 抑制MYC导致CD47和PD- L1在mRNA和蛋白质水平上的表达减少.
- 证明MYC直接与Cd47和Pd-l1基因的促进子区域结合.
- 在瘤中MYC的无活化增强了抗瘤免疫反应.
- 在MYC失活的瘤中强制表达CD47或PD- L1取消了增强的免疫反应并促进了瘤的生长.
结论:
- 通过调节免疫检查点蛋白CD47和PD- L1的表达,MYC在瘤发生中发挥着重要作用.
- MYC对这些免疫检查点的调节对于免疫逃避和瘤进展至关重要.
- 向MYC可能是增强抗瘤免疫力的治疗策略.
相关概念视频
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
01:27Tumor Immunotherapy
2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
01:06Induced Pluripotent Stem Cells
6.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
6.2K
01:31The Intrinsic Apoptotic Pathway
9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
02:38Mitogens and the Cell Cycle
8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K